New geographies and more care
Australia growth
We opened two new cancer centres in Australia at Noosa, South-East Queensland and The Bays in Victoria’s Mornington Peninsula Shire, bringing our national total to 40 cancer centres.Our established national network also saw the continued introduction of new technologies including significant uplift in stereotactic radiotherapy treatments as well as second linear accelerator installations at existing cancer centres to meet growing demand.
We celebrated significant service milestones with Icon Cancer Centre Gold Coast University’s 10th birthday and one-year anniversaries for Icon Cancer Centre Mildura, Victoria and Auchenflower, Queensland. We also announced development of new centres including a radiation therapy service at St Vincent’s Hospital in Ipswich, Queensland and a centre at New Epping in North Richmond, Victoria, alongside construction of our first CyberKnife location in Melbourne as part of our joint venture with 5D Clinics.
ASEAN expansion
Icon continued to see sustainable growth in the ASEAN region. Icon Cancer Centre, Mt Alvernia celebrated one year of service highlighting the strength of Icon’s integrated model of cancer care under one roof. The centre has also become a hub for clinical trials and continues to attract highly experienced visiting consultants and international research opportunities.2024 also saw the opening of our first cancer centre in Penang, Malaysia as part of our joint venture with Sunsuria Healthcare. This centre has seen exponential growth in patient numbers and has set solid foundations for further developments in the region.
A focus in the United Kingdom
We strengthened our focus in the United Kingdom with the acquisition of Pharmaxo Group, a leading pharmaceutical specialist manufacturer and clinical homecare provider based in Corsham, Wiltshire. This acquisition underscored our commitment to improving healthcare in the region and building on Icon’s integrated model of care. We closed out the year with the acquisition of Nuffield Health’s Cancer Centre London, building on our strategic partnership with Nuffield to deliver more timely cancer care across England.
Operational excellence
Accreditation success
Our Research division achieved an Australian first, attaining dual global quality certifications for research sites and workforce leadership. The Global Quality Standard for Clinical Research Sites (GCSA) demonstrates Icon’s commitment to the highest global best-practice research standards.
Similarly, Icon Cancer Centre Singapore received three year accreditation by Australian Council on Healthcare Standards International and our cancer centres in Australia and New Zealand were praised by accreditation accessors, exceeding national standards.
Best in class pharmacy and compounding services
Icon’s national pharmacy network underwent a brand harmonisation with the majority of Epic pharmacies now under the Slade brand, delivering a strong network of 70+ Slade Pharmacies nationally. This alignment reflects the strength of the Slade brand and the breadth of pharmacy capability.
Slade Pharmacy also achieved national accreditation for Advanced Pharmacy Australia’s Resident Training Program, highlighting our strong reputation and commitment to nurturing young pharmacists. Slade Health’s Woodville centre also celebrated one year since opening, dispatching more than 650 compounding products daily.
Our compounding and pharmacy divisions continued to roll out digital solutions and maintain strong hospital partnerships to quality patient care our partners can rely on.
Expanding our doctor network
We continued to welcome new doctors and clinical leadership including our Chief Medical Officer for the UK, Dr Penny Kechagioglou, Dr Karthik Nath our Deputy Director of Cellular Therapy and the new role of Clinical Director for Molecular Imaging and Nuclear Oncology, Dr Nat Lenzo.
These high-profile appointments and ever-growing 350+ doctor network highlight our patient-focused, clinician-led values and ensure we remain at the forefront of cancer care.
Award winning healthcare
Icon were finalists in a number of industry awards and claimed wins at – Australian Private Hospitals Association Excellence Awards for Icon Cancer Centre Australia’s Survivorship Pilot Program, Icon Cancer Centre Singapore won AustCham’s Business Excellence Award and our Icon Centre Rockingham team won at the South Metropolitan Health Service Excellence Awards, winning the Excellence in Strengthening Partnerships category.
Future healthcare
Investment in technology and AI
Through our long-term global partnership with industry leaders, Varian Medical Systems, Icon continued to introduce first to market technology to our global cancer care network.
We also signed new partnerships including Radformation, a global pioneer of radiation oncology software solutions and SeeTreat to pioneer precision radiation therapy. These partnerships have resulted in the successful adoption of AI Contouring for radiotherapy plans and continued discovery of AI within cancer care, improving efficiencies whilst maintaining the highest standard of patient care.
Connecting with our communities
We strengthened our partnerships with patient advocacy groups including Rare Cancers Australia, Bowel Cancer Australia and Prostate Cancer Foundation Australia. This saw the welcome introduction of specialist nurses across our Australia centres and growing collaboration to continue improving the patient experience.
Icon Cancer Centre Singapore extended their MOU with 365 Cancer Prevention Society cemented a long-term commitment to supporting cancer patients in the region.
Icon Group also became a Premier Associate Member of the International Hospital Federation (IHF), underscoring Icon’s position as a leader in healthcare and enhancing collaboration with leading hospitals around the world.
Research
2024 also marked the launch of our theranostics research program, increasing access to precision medicine and international clinical trials. This program will bring new trials to Australia, Singapore and beyond.
Dr Pat Bowden’s published TRANSFORM trial found stereotactic radiotherapy can delay the need for more traditional forms of therapy, such as hormone and chemotherapy.
Medical Oncologist, A/Prof Louise Nott was nominated and recognised as a finalist in the 2025 Australia of the Year Awards for Tasmania for her work in clinical trials and establishment of a comprehensive trials unit at Icon Cancer Centre Hobart.
We doubled down on our research commitment, relaunching our not-for-profit, Icon Cancer Foundation, including the award of two inaugural grants to research projects at Icon Cancer Centre Australia.
Looking ahead to 2025, Icon will continue to invest in clinical trials across all modalities and increase access to emerging treatments.
Delivering world-class care that feels like family
Icon Group CEO, Mark Middleton OAM reflects on a transformative year.
“We’ve had a huge year of delivering care and it’s thanks to our dedicated people that more families and communities have access to world-class care that feels like family,” said Mark.
“Next year will continue to invest in regions where we can sustainably introduce Icon’s proven model of comprehensive care and turn the dial on the growing cancer burden.”
